Early non-responders in teriparatide therapy: retrospective analysis
Authors:
Masaryk Pavol; Letkovská Alexandra
Authors place of work:
Národný ústav reumatických chorôb, Piešťany
Published in the journal:
Clinical Osteology 2020; 25(1): 45-49
Category:
Summary
Teriparatide (TPTD) is a potent osteoanabolic drug. A potential drawback associated with teriparatide treatment is a failure of effect. The incidence of non-responders depends on the definition of lack of response to treatment, baseline bone density, duration of treatment, prior antiresorptive therapy, and measurement accuracy. In our study, we analyzed “early non-responders” after 6 and 12 months of treatment in a group of 306 patients. We identified 36 (11.7 %) patients as early non-responders, of whom 18 after 6 months of treatment and 18 after one year of treatment. There were only 4 men and up to 32 women in the sample, but the percentage of non-responders among the sexes was approximately the same (men: 10.5 %, women: 11.9 %). Early non-responders in glucocorticoid osteoporosis were significantly more represented. Previous antiresorptive therapy, especially bisphosphonates, increased the risk of a lack of response to teriparatide therapy.
Keywords:
teriparatide – non-responders
Zdroje
Eriksen EF, Keaveny TM, Gallagher ER et al. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014; 67: 246–256. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2014.07.014>.
Dempster DW, Cosman F, Parisien M et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14(6): 690–709. Dostupné z DOI: <http://dx.doi.org/10.1210/edrv-14–6-690>.
Body JJ, Gaich GA, Scheele WH et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2000; 87(10): 4528–4535. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–020334>.
Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>.
Gallagher JC, Rosen CJ, Chen P et al. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006; 39(6): 1268–1275. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2006.06.007>.
Heaney RP, Watson P. Variability in the measured response of bone to teriparatide. Osteoporos Int 2011; 22(6): 1703–1708. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–010–1376–1>.
Elraiyah T, Ahmed AH, Wang Z et al. Predictors of teriparatide treatment failure in patients with low bone mass. Bone Reports 2016; 4: 17–22. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bonr.2015.11.001>.
Payer J, Tomková S, Jackuliak P et al. Teriparatid v liečbe ťažkej osteoporózy u starších pacientok: výsledky multicentrickej prospektívnej štúdie. Clin Osteol 2018; 23(3): 88–93.
Payer J, Tomková S, Killinger Z et al. 18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTEO.sk). Clin Osteol 2018; 23(4): 138–145.
Minne H, Audran M, Maria E et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008; 24(11): 3117–3128. Dostupné z DOI: <http://dx.doi.org/10.1185/03007990802466595>.
Niimi R, Kono T, Nishihara TA et al. A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int 2016; 27(9): 2845–2853. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–016–3581-z>. Erratum in Erratum to: A retrospective analysis of nonresponse to daily teriparatide treatment.
Niimi R, Kono T, Nishihara A et al. Osteoporos Int 2016; 27(9): 2887–2888. Dostupné z DOI: <http://dx.doi.oerg/10.1007/s00198–016–3625–4>.
Kim SY, Zhang M, Bockman R. Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSSJ 2017; 13(2): 171–177. Dostupné z DOI: <http://dx.doi.org/10.1007/s11420–016–9537–1>.
Cohen A, Stein EM, Recker RR et al. Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study. J Clin Endocrinol Metab 2013; 98(5): 1971–1981. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–1172>.
Ettinger B, San Martin J, Crans G et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19(5): 745–751. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.040117>.
Lindsay R, Zhou H, Cosman F et al. Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007; 22(4): 495–502. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.070104>.
Borggrefe J, Graeff C, Nickelsen T N el al. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010; 25(3): 472–481. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.090820>.
Štítky
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyČlánok vyšiel v časopise
Clinical Osteology
2020 Číslo 1
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Memantine Eases Daily Life for Patients and Caregivers
- Metamizole vs. Tramadol in Postoperative Analgesia
Najčítanejšie v tomto čísle
- Atypical cases of secondary hyperparathyroidism in patients with kidney disease and failure: case reports
- Guidelines for osteoporotic patients during COVID-19 pandemics
- Effect of anorexia nervosa on bone metabolism
- Management of osteoporosis and calcium metabolism disorders during COVID-19 pandemics